Loading
TENT5C (Terminal nucleotidyltransferase 5C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Skin cancer, Colorectal cancer and 1 more.
Catalyses the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group and enhances mRNA stability and gene expression. Can also elongate RNA oligos ending with uridine molecule, provided that the sequence is adenosine-rich. Mainly targets mRNAs encoding endoplasmic reticulum-targeted protein.
Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.92, animal model 0.44, genetic association 0.10, somatic mutation 0.92). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Plasma Cell Myeloma.
In plain words · TENT5C (Terminal nucleotidyltransferase 5C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Skin cancer, Colorectal cancer and 1 more.
TENT5C (Terminal nucleotidyltransferase 5C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Skin cancer, Colorectal cancer and 1 more.
Catalyses the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group and enhances mRNA stability and gene expression.
No product in this corpus aims at TENT5C yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
First described 2004. Earliest sequence paper UniProt cites for the protein: Ota et al, Nat. Genet, 2004, "Complete sequencing and characterization of 21,243 full-length human cDNAs". Source.
Sources: HGNC HGNC:24712 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q5VWP2 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000183508 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: colorectal cancer 0.51, plasma cell myeloma 0.54, skin cancer 0.52, lung cancer 0.50 (GraphQL API, CC0)); IntOGen TENT5C (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Catalyses the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group and enhances mRNA stability and gene expression. Can also elongate RNA oligos ending with uridine molecule, provided that the sequence is adenosine-rich. Mainly targets mRNAs encoding endoplasmic reticulum-targeted protein. Location: Nucleus; Cytoplasm; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome (UniProt). Locus 1p12 (HGNC).
Query for this target: (TITLE:"TENT5C" OR ABSTRACT:"TENT5C" OR TITLE:"terminal nucleotidyltransferase 5C" OR ABSTRACT:"terminal nucleotidyltransferase 5C" OR TITLE:"Terminal nucleotidyltransferase 5C" OR ABSTRACT:"Terminal nucleotidyltransferase 5C" OR TITLE:"FLJ20202" OR ABSTRACT:"FLJ20202" OR TITLE:"FAM46C" OR ABSTRACT:"FAM46C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TENT5C, not a curated reading list.